169 related articles for article (PubMed ID: 31990069)
1. Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report.
Horai Y; Ishikawa H; Iwanaga N; Izumi Y; Matsuoka Y; Miura S; Kawakami A
J Clin Pharm Ther; 2020 Oct; 45(5):1179-1182. PubMed ID: 31990069
[TBL] [Abstract][Full Text] [Related]
2. Successful Treatment of Hypocomplementemic Urticarial Vasculitis With Omalizumab: A Case Report.
Pérez Codesido S; Rosado Ingelmo A; Gómez de la Fuente E; García García E; Privitera Torres M; Tejedor Alonso MA
J Investig Allergol Clin Immunol; 2020 Jun; 30(3):211-212. PubMed ID: 32571766
[No Abstract] [Full Text] [Related]
3. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
[TBL] [Abstract][Full Text] [Related]
5. [Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: Interim analysis of post-marketing surveillance].
Kameda H; Nishida K; Nannki T; Watanabe A; Oshima Y; Momohara S
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(3):196-205. PubMed ID: 28747607
[TBL] [Abstract][Full Text] [Related]
6. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
Curtis JR; Winthrop K; O'Brien C; Ndlovu MN; de Longueville M; Haraoui B
Arthritis Res Ther; 2017 Dec; 19(1):276. PubMed ID: 29246162
[TBL] [Abstract][Full Text] [Related]
7. A rheumatoid arthritis patient with delivery who started certolizumab pegol and tacrolimus during pregnancy.
Ito S; Ishikawa H; Kato R
Mod Rheumatol Case Rep; 2022 Jan; 6(1):6-9. PubMed ID: 34477867
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
Tanaka Y; Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Int J Rheum Dis; 2020 Mar; 23(3):316-324. PubMed ID: 31957303
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients.
Förger F; Zbinden A; Villiger PM
Joint Bone Spine; 2016 May; 83(3):341-3. PubMed ID: 26617214
[TBL] [Abstract][Full Text] [Related]
10. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis.
Domańska B; VanLunen B; Peterson L; Mountian I; Schiff M
Expert Opin Drug Deliv; 2017 Jan; 14(1):15-22. PubMed ID: 27801596
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland.
Kumar N; Naz S; Quinn M; Ryan J; Kumke T; Sheeran T
Adv Ther; 2018 Sep; 35(9):1426-1437. PubMed ID: 30076523
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
[TBL] [Abstract][Full Text] [Related]
14. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
16. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab Pegol-Induced Heart Failure.
Lazarewicz K; Shaw S; Haque S
J Clin Rheumatol; 2018 Jan; 24(1):55-56. PubMed ID: 29232326
[No Abstract] [Full Text] [Related]
18. Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis.
Takeuchi T; Yamamoto K; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Kobayashi M; Shoji T; Togo O; Miyasaka N; Koike T
Mod Rheumatol; 2016 Jul; 26(4):473-80. PubMed ID: 26472043
[TBL] [Abstract][Full Text] [Related]
19. Possible relationship between certolizumab pegol and arrhythmias: report of two cases.
Talotta R; Atzeni F; Batticciotto A; Ventura D; Sarzi-Puttini P
Reumatismo; 2016 Sep; 68(2):104-8. PubMed ID: 27608800
[TBL] [Abstract][Full Text] [Related]
20. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
Weinblatt ME; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; VanLunen B; Ecoffet C; Cioffi C; Emery P
Arthritis Rheumatol; 2017 Oct; 69(10):1937-1948. PubMed ID: 28666080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]